1月15日(火) | 17:45 - 20:45
While great strides have been made in CAR functionality, much remains to be done in expanding the reach of CARs beyond hematologic malignancies, addressing tumor escape by engineering multiple CAR targets, and building regulatory capacities into CAR cells to avoid toxicity issues. This course explores the past, present, and future of CAR design with an eye toward making CARs a “plug and play” system and circumventing the empirical and expensive CAR optimization previously required for clinical relevance.
Brian Webster, PhD, R&D Scientist, Lentigen Technology
CHI’s “Structure-Based Optimization of Antibodies” is a 3-hour lecture offering a quick overview to the concepts, strategies and tools of structure-based optimization of antibodies. This lecture will cover structure-based techniques to modulate affinity, create novel constructs (such as Fc-fusions, bispecifics, etc.) along with increasing the manufacturability of a biologic. The class is directed at scientists new to the industry, academic scientists, and career protein engineers wanting a quick overview about how structure can aid in guiding experimental design.
Christopher Corbeil, PhD, Research Officer, Human Health Therapeutics, National Research Council Canada
SC3: タンパク質凝集： 機序、特性化、帰結
Protein aggregation is recognized by regulatory agencies and the biopharmaceutical industry as a key quality attribute of biotherapeutics. Various aggregates hold the potential for adversely impacting production and patients in a variety of ways. This in-depth course reviews the origins and consequences of aggregation in biotherapeutics, and then examines strategies for predicting and quantifying aggregation in biopharmaceuticals. It benefits scientists engaged in development, production, analytical characterization and approval of biotherapeutics, and who require a good working knowledge of protein aggregation.
Thomas Laue, PhD, Professor Emeritus, Biochemistry and Molecular Biology; Director, Biomolecular Interaction Technologies Center (BITC), University of New Hampshire
All protein drugs generate an immunogenic response. This short course provides a practical, comprehensive overview of immunogenicity – the causes, how to assess, predictive tools and what to do if you observe immunogenicity during preclinical, clinical and post-market approval. Focus will also be given to immunogenicity for immuno-oncology therapies.
Sofie Pattijn, CTO, ImmunXpert
A variety of mature protein production systems exist that can be used to create an expression toolbox to address protein production challenges. This short course focuses on transient protein production in mammalian cells including the concepts, technologies, and optimization strategies needed for the rapid generation of milligram-to-gram quantities of secreted or intracellular recombinant proteins for therapeutic, functional, and structural studies. The course combines instruction and case studies in an interactive environment directed towards intermediate-level scientists, but is still appropriate for expression scientists of all experience levels.
Richard Altman, MS, Scientist, Protein Technologies, Amgen
Henry C. Chiou, PhD, Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific
Additional Instructors to be Announced
*Separate registration required